<DOC>
	<DOC>NCT00847301</DOC>
	<brief_summary>An observational cohort study on safety and efficacy to generate additional data on the benefit/risk profile of the 150 mg dose of Pradaxa in patients with renal impairment</brief_summary>
	<brief_title>Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criteria: Patients of 18 years of age or above with moderate renal impairment (creatinine clearance 3050 ml/min) undergoing elective total hip replacement surgery who consent in writing to their participation in this observational study Exclusion criteria: All patients who should not be treated with Pradaxa 150 mg according to the European Summary of Product Characteristics (SPC): severe renal impairment (creatinine clearance &lt; 30 ml/min); elevated liver enzymes &gt; 2 upper limit of normal (ULN); Hepatic impairment or liver disease expected to have any impact on survival, anaesthesia with postoperative indwelling epidural catheters, hypersensitivity to dabigatran etexilate or to any of the excipients, active clinically significant bleeding, organic lesion at risk of bleeding, spontaneous or pharmacological impairment of haemostasis, concomitant treatment with quinidine, protehetic heart valve requiring anticoagulant treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>